Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Genprex, Inc.

Get SEC filing alerts via email and in your feed for Genprex, Inc.

GNPX

Genprex, Inc.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage biotechnology company developing gene therapies for cancer and diabetes. Its oncology platform uses non-viral lipid nanoparticles to deliver tumor suppressor genes, aiming to treat lung cancers and other solid tumors. The company's diabetes program focuses on gene therapies to regenerate insulin-producing cells. Its business model centers on innovative gene delivery systems, clinical trials, and strategic collaborations.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Genprex, Inc.

1
1
Genprex, Inc. Genprex Reports $4.46 Million Net Loss in Q1 2026, Highlights Increased R&D Expenses

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Genprex, Inc. Genprex Reports $16.2 Million Net Loss for 2025, Decrease Attributed to Expense Reductions

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Genprex, Inc. Genprex Reports $3.8 Million Net Loss in Q3 2025, Down 12% Year-Over-Year

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Genprex, Inc. Genprex Reports $4.67 Million Net Loss in Q2 2025, Down 28% Year-Over-Year

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Genprex, Inc. Genprex Reports $3.96 Million Net Loss in Q1 2025, Decreases Operating Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Genprex, Inc. Genprex Reports $21.1 Million Net Loss for Fiscal Year 2024, Advances Oncology Trials

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Genprex, Inc. Genprex Reports Significant Financial Decline, Reduced Workforce, and Ongoing Clinical Trials

Via official filing (AI summary) | over 1 year ago | 0 comments